Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT1 | P54687 | 15/20 | 0.41 |
| ▸ | BCAT2 | O15382 | 13/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7462831 | 0.85 | BCAT1 (0.39) | BCAT1BCAT2SMN1; SMN2ALDH1A1CYP2C9 | |
| SCHEMBL6974181 | 0.79 | BCAT1 (0.42) | BCAT1BCAT2 | |
| SCHEMBL6770530 | 0.78 | BCAT1 (0.40) | BCAT1BCAT2SMN1; SMN2ALDH1A1CYP2C9 | |
| SCHEMBL7459552 | 0.78 | BCAT2 (0.44) | BCAT1BCAT2 | |
| SCHEMBL6770607 | 0.77 | MAPT (0.33) | — | |
| SCHEMBL7462542 | 0.76 | BCAT1 (0.46) | BCAT1BCAT2 | |
| SCHEMBL6767866 | 0.76 | BCAT1 (0.40) | BCAT1BCAT2SMN1; SMN2ALDH1A1 | |
| SCHEMBL7462374 | 0.75 | BCAT1 (0.42) | BCAT1BCAT2ALDH1A1CYP2C9 | |
| SCHEMBL7462378 | 0.75 | BCAT1 (0.44) | BCAT1BCAT2 | |
| SCHEMBL8898389 | 0.73 | BCAT1 (0.42) | BCAT1BCAT2SMN1; SMN2ALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6706663-B2 | CHEMICAL INTERMEDIATES | WYETH | 2004-03-16 | — | — | US | disclosed |
| EP-0908457-B1 | 3-(1,2-benzisothiazol- and isoxazol-5-Y1)-2,4(1H,3H)-pyrimidinedione or thione and 3-(1,2-benzisothiazol- and isoxazol-5-y1)-4(3H)-pyrimidinone or thione herbicidal agents | BASF AG (DE) | 2002-11-13 | — | — | EP | disclosed |
| US-6355796-B1 | REACTING BETA-AMINO-BETA-(PERFLUOROALKYL)ACRYLATE COMPOUND WITH BASE AND CARBAMOYL CHLORIDE COMPOUND TO FORM UREA COMPOUND, REACTING UREA COMPOUND WITH PHOSPHORUS PENTAHALIDE OR OXALYL HALIDE | BASF AKTIENGESELLSCHAFT (DE) | 2002-03-12 | — | — | US | disclosed |
| US-20020028748-A1 | Herbicidal 3 -heterocyclic substituted benzisothiazole and benzisoxazole compounds | INTELLECTUAL PROPERTY DEPARTMENT BASF AKTIENGESELLSCHAFT (DE) | 2002-03-07 | — | — | US | disclosed |
| US-6156700-A | 3-(1,2-Benzisothiazol- and isoxazol-5-yl)-2,4(1H,3H)-pyrimidinedione or thione and 3-(1,2-benzisothiazol- and isoxazol-5-yl)-4(3H)-pyrimidinone or thione herbicidal agents | AMERICAN CYANMID COMPANY (US) | 2000-12-05 | — | — | US | disclosed |
| EP-0908457-A1 | 3-(1,2-benzisothiazol- and isoxazol-5-Y1)-2,4(1H,3H)-pyrimidinedione or thione and 3-(1,2-benzisothiazol- and isoxazol-5-y1)-4(3H)-pyrimidinone or thione herbicidal agents | American Cyanamid Company (US) | 1999-04-14 | — | — | EP | disclosed |
| WO-1999014216-A1 | SUBSTITUTED 3(-1,2-BENZISOTHIAZOL OR ISOXAZOL-5 YL)-SUBSTITUTED PYRIMIDINE AS HERBICIDES | AMERICAN CYANAMID COMPANY (US) | 1999-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028748-A1 | Herbicidal 3 -heterocyclic substituted benzisothiazole and benzisoxazole compounds | CYP4X1, HAX1, DDT | BCAT1 281/4885BCAT2 276/4885SMN1; SMN2 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.